Imojev

AXP000207.1 · Vaccine

Platform
chimeric yellow fever 17D-Japanese encephalitis virus (ChimeriVax)
Targets
JEV prM/E
Originator
Acambis (ChimeriVax platform) / Sanofi Pasteur
Sponsor
Sanofi Pasteur

Names

NameTypeSource
Imojevpreferred name, brandcurator, curator
Imojev MDbrandcurator
JE-CVcodecurator
ChimeriVax-JEformer codecurator

Virus

Role
Vaccine vector
Family
Flaviviridae
Virus
yellow fever virus (NCBI Taxonomy 11089)
Strain
17D-204 backbone (JE-CV chimera)
Replication
replicating
Modifications
prM and E genes of YF 17D-204 replaced by those of Japanese encephalitis virus SA14-14-2
Transgenes
JEV prM/E
Route
subcutaneous
Source
evidence

Approvals

AgencyRegionDateStatusBrandIndicationSource
otherTH2012approvedImojevActive immunisation against Japanese encephalitis from 12 months of agesource
TGAAU2012approvedImojevActive immunisation against Japanese encephalitis from 12 months of agesource

Clinical trials (19)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06680128A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy AdultsCompletedPhase 1/22025-02-242026-07-31161Japanese Encephalitis Virus Disease
NCT05568953An Experimental Medicine Decipher of a Minimum Correlate of Cellular ImmunityUnknownPhase 22022-09-282025-1070Infectious Disease; Japanese Encephalitis; Viral Infection; Yellow Fever
NCT03920111Flavivirus Cross-priming Potential of IMOJEVCompleted2021-04-162021-12-2319Japanese Encephalitis
NCT02933710Postmarketing Surveillance Study for IMOJEV® in Republic of KoreaCompleted2016-07-212018-10-1850Japanese Encephalitis
NCT02492165Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy SubjectsCompletedPhase 32015-062016-03250Japanese Encephalitis
NCT02526550Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAXCompletedPhase 42014-062014-0750Encephalitis
NCT01981967Post-licensure Safety Study of IMOJEV® in ThailandCompletedPhase 42013-112015-0410000Japanese Encephalitis
NCT01954810Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in ChildrenUnknownPhase 42013-102013-1288Japanese Encephalitis
NCT01900444Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South KoreaCompletedPhase 32013-07-112014-03-11119Japanese Encephalitis
NCT01396512Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in ToddlersCompletedPhase 32011-072013-03274Japanese Encephalitis; Japanese Encephalitis Virus Disease
NCT01190228Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CVCompletedPhase 32010-08-252010-10-29454Japanese Encephalitis; Varicella
NCT01188343Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese ToddlersCompletedPhase 32010-082012-07542Japanese Encephalitis; Measles; Mumps; Rubella
NCT01092507A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and ToddlersCompletedPhase 32010-032011-09300Encephalitis; Japanese Encephalitis
NCT01001988Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in ToddlersCompletedPhase 32009-08-072013-10-16596Encephalitis; Japanese Encephalitis
NCT00735644Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the PhilippinesCompletedPhase 32008-082009-051200Hepatitis A; Japanese Encephalitis
NCT00621764Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and ChildrenCompletedPhase 22008-032009-12300Hepatitis A; Japanese Encephalitis
NCT00441259Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending AgeCompletedPhase 22007-012011-0296Japanese Encephalitis
NCT00314132Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.CompletedPhase 32005-102006-112004Encephalitis; Japanese Encephalitis
NCT00982137Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)CompletedPhase 22004-072005-04108Japanese Encephalitis; Yellow Fever
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT02602652Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 VaccineCompleted2013-122015-0750Japanese Encephalitisname in title: JE-CV

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 39794472Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans.Nature microbiology2025cited by trial NCT05568953
PMID 36308439Immunogenicity of a single fractional intradermal dose of Japanese encephalitis live attenuated chimeric vaccine.Journal of travel medicine2023name in abstract: Imojev
PMID 36969244An experimental medicine decipher of a minimum correlate of cellular immunity: Study protocol for a double-blind randomized controlled trial.Frontiers in immunology2023cited by trial NCT05568953
PMID 32474892Post-Marketing Surveillance of Adverse Events Following Vaccination with the Live-Attenuated Japanese Encephalitis Chimeric Virus Vaccine (Imojev®) in South Korea, 2015-2019.Infectious diseases and therapy2020cited by trial NCT02933710
PMID 29081368Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: A single-arm, single-center study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2018cited by trial NCT02492165
PMID 29325161Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV-Primed Children in the Philippines.The Journal of infectious diseases2018cited by trial NCT01190228
PMID 27815383Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization.The Journal of infectious diseases2017cited by trial NCT00621764
PMID 27846060Immunogenicity of a Live Attenuated Chimeric Japanese Encephalitis Vaccine as a Booster Dose After Primary Vaccination With Live Attenuated SA14-14-2 Vaccine: A Phase IV Study in Thai Children.The Pediatric infectious disease journal2017cited by trial NCT02526550
PMID 27903416Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand.Vaccine2017cited by trial NCT01981967
PMID 28030526Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization.The Pediatric infectious disease journal2017name in abstract: Imojev
PMID 27686833Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.Vaccine2016cited by trial NCT00621764
PMID 24631095Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan.Vaccine2014name in title: JE-CV
PMID 24656175Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India.BMC infectious diseases2014cited by trial NCT00735644
PMID 24717964Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety.The Pediatric infectious disease journal2014cited by trial NCT01092507
PMID 25483480A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.Human vaccines & immunotherapeutics2014cited by trial NCT01396512
PMID 23442823Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children.Human vaccines & immunotherapeutics2013name in title: JE-CV
PMID 22777096Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial.Human vaccines & immunotherapeutics2012cited by trial NCT00735644
PMID 20856164Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial.The Pediatric infectious disease journal2010cited by trial NCT00621764
PMID 20864814Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.Human vaccines2010cited by trial NCT00982137
PMID 20934459Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials.Vaccine2010cited by trial NCT00314132
PMID 14551893Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.The Journal of infectious diseases2003name in title: ChimeriVax-JE
PMID 11803060Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.Vaccine2002name in abstract: ChimeriVax-JE
Unconfirmed matches (4)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 32522414Immunogenicity and safety of two-visit, intradermal pre-exposure rabies prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis vaccine in children living in rabies and Japanese encephalitis endemic country.Vaccine2020name in abstract: JE-CV
PMID 26535878Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.The Pediatric infectious disease journal2016name in abstract: JE-CV
PMID 27628323Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.Vaccine2016name in abstract: JE-CV
PMID 21150279Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults.Human vaccines2010name in abstract: JE-CV

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41754514mRNA Vaccine Against Japanese Encephalitis Virus Genotype IV Protects Against Lethal Infection.Viruses2026name in abstract: Imojev
PMID 41755551Japanese Encephalitis: Understanding Its Impact, Prevention, and the Role of Vaccination.Reviews in medical virology2026name in abstract: Imojev
PMID 39836415Long-term immunogenicity of a single-dose live recombinant chimeric Japanese encephalitis vaccine in adults.Journal of travel medicine2025name in abstract: Imojev
PMID 40252364Knowledge-based mitigation of the environmental risk of Orthoflavivirus live-attenuated vaccines by targeting viral encoded determinants for the mosquito attenuated phenotype.Vaccine2025name in abstract: Imojev
PMID 40982537Antibody responses to Japanese encephalitis virus and dengue virus serotype 2 in children from an orthoflavivirus endemic region after IMOJEV vaccination.PLoS neglected tropical diseases2025name in title: Imojev
PMID 39353860Long-term immunogenicity of the SA14-14-2 Japanese encephalitis (JE) vaccine (CD.JEVAX®) booster following chimeric JE (IMOJEV®) vaccine priming in Thai children.Human vaccines & immunotherapeutics2024name in title: Imojev
PMID 40295675Characterisation of a Japanese Encephalitis virus genotype 4 isolate from the 2022 Australian outbreak.Npj viruses2024name in abstract: Imojev
PMID 35254947Safety profile comparison of chimeric live attenuated and Vero cell-derived inactivated Japanese encephalitis vaccines through an active surveillance system in Australia.Human vaccines & immunotherapeutics2022name in abstract: Imojev
PMID 35415706Investigation of immune response induction by Japanese encephalitis live-attenuated and chimeric vaccines in mice.MedComm2022name in abstract: ChimeriVax-JE
PMID 34834244Immunological Analysis of Nodavirus Capsid Displaying the Domain III of Japanese Encephalitis Virus Envelope Protein.Pharmaceutics2021name in abstract: Imojev
PMID 32265332A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.mBio2020name in abstract: Imojev
PMID 32546414Adverse events following immunization with the live-attenuated recombinant Japanese encephalitis vaccine (IMOJEV®) in Taiwan, 2017-18.Vaccine2020name in title: Imojev
PMID 30230947Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine.Human vaccines & immunotherapeutics2019name in abstract: Imojev
PMID 26588242Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children.Expert review of vaccines2016name in title: Imojev
PMID 25841620Current recommendations for the Japanese encephalitis vaccine.Journal of the Chinese Medical Association : JCMA2015name in abstract: Imojev
PMID 25134477Japanese B Encephalitis: An Overview of the Disease and Use of Chimerivax-JE as a Preventative Vaccine.Infectious diseases and therapy2013name in title: ChimeriVax-JE
PMID 22775524Clinical development of IMOJEV ®--a recombinant Japanese encephalitis chimeric vaccine (JE-CV).Expert opinion on biological therapy2012name in title: Imojev
PMID 21434803New Japanese encephalitis vaccines: alternatives to production in mouse brain.Expert review of vaccines2011name in abstract: Imojev
PMID 19913267Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirus.Virology2010name in abstract: ChimeriVax-JE
PMID 20130134An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.The Journal of general virology2010name in abstract: ChimeriVax-JE
PMID 20218889Japanese encephalitis: new options for active immunization.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2010name in abstract: ChimeriVax-JE
PMID 21105774IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.Expert review of vaccines2010name in title: Imojev
PMID 21308526New vaccines for Japanese encephalitis.Current infectious disease reports2010name in abstract: ChimeriVax-JE
PMID 19109382Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus.Journal of virology2009name in abstract: ChimeriVax-JE
PMID 19768415Microneedle-based vaccines.Current topics in microbiology and immunology2009name in abstract: ChimeriVax-JE
PMID 17303204A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus.Virology2007name in abstract: ChimeriVax-JE
PMID 17693000Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE).Vaccine2007name in title: ChimeriVax-JE
PMID 17038690Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE).The American journal of tropical medicine and hygiene2006name in title: ChimeriVax-JE
PMID 15975826Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys.Biologicals : journal of the International Association of Biological Standardization2005name in abstract: ChimeriVax-JE
PMID 16273137Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2005name in abstract: ChimeriVax-JE
PMID 17012854Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates.Human vaccines2005name in title: ChimeriVax-JE
PMID 15176941A chimeric live attenuated vaccine against Japanese encephalitis.Expert review of vaccines2004name in abstract: ChimeriVax-JE
PMID 15315852Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine.Vaccine2004name in title: ChimeriVax-JE
PMID 12949633Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2003name in abstract: ChimeriVax-JE
PMID 14508887ChimeriVax-JE. Acambis.Current opinion in investigational drugs (London, England : 2000)2003name in title: ChimeriVax-JE
PMID 11799188Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines.Journal of virology2002name in abstract: ChimeriVax-JE
PMID 12082985Japanese encephalitis vaccines: current vaccines and future prospects.Current topics in microbiology and immunology2002name in abstract: ChimeriVax-JE
PMID 11134306Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).Journal of virology2001name in title: ChimeriVax-JE
PMID 10644345Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.Journal of virology2000name in abstract: ChimeriVax-JE
PMID 11220763Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes.The American journal of tropical medicine and hygiene2000name in title: ChimeriVax-JE
PMID 10217584Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.Vaccine1999name in abstract: ChimeriVax-JE
PMID 10329547Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.Virology1999name in title: ChimeriVax-JE
Unconfirmed matches (5)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 42363922Japanese Encephalitis Vaccine Preferences and Uptake in Western Travelers and Locals: Strategies to Enhance Vaccine Uptake.Value in health regional issues2026name in abstract: JE-CV
PMID 42728503Immunogenicity of a Vero cell-adapted Japanese encephalitis attenuated virus strain SA14-14-2 VC6.Archives of virology2026name in abstract: JE-CV
PMID 37782654Epidemiology and risk factors of Japanese encephalitis in Taiwan, 2010-2022.PLoS neglected tropical diseases2023name in abstract: JE-CV
PMID 33974924Feasibility of chitosan-based nanoparticles approach for intranasal immunisation of live attenuated Japanese encephalitis vaccine.International journal of biological macromolecules2021name in abstract: JE-CV
PMID 22342547Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine.Vaccine2012name in abstract: JE-CV

NIH grants

ProjectTitleOrganisationPIYearsLinked by
U01AI070350Stable Micronized Vaccines Against Smallpox and Japanese EncephalitisUNIVERSAL STABILIZATION TECHNOLOGIESBRONSHTEIN, VICTOR2006–2008name in abstract: ChimeriVax-JE

Notes

Live chimeric virus: yellow fever 17D-204 backbone with the prM and E genes of JEV SA14-14-2. Same 'carries something foreign' reasoning as CYD-TDV. Single subcutaneous dose from 12 months of age. WHO-prequalified 2014-09-18 with the Thai FDA as national regulatory authority of record. Exact national approval dates were not found on an agency page; the Thai and Australian rows are dated 2012 from the launch press releases that state marketing authorisation had been granted.

How to cite

Imojev (AXP000207.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000207.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.